← All Compounds
Mechanism Synthetic analog of ACTH (4-10) fragment. Enhances BDNF expression, modulates dopaminergic and serotonergic systems, provides neuroprotective effects. Does not affect adrenal cortex function despite ACTH origin. Half-Life Approximately 3-5 minutes (intranasal bioavailability extends effective duration) Route subcutaneous Frequency Once daily (intranasal or SC)
FDA Category Research peptide in US (removed from FDA Category 2; approved in Russia) Reclassification removed-from-cat2 Date Restricted 2023-09-29 Announced Return 2026-02-27
Inclusion of a compound does not constitute endorsement. Information sourced from published research and regulatory filings.
Semax
Removed from Cat 2
Neuropeptide · Research peptide (approved in Russia as Semax)
Synthetic analog of ACTH (4-10) fragment researched for neuroprotective and cognitive-enhancing effects. Approved in Russia; not FDA-approved in the US.
About
Clinical Dosing
200-600 mcgonce daily (intranasal or sc)
Removed from Category 2 by FDA (April 15, 2026). Will be evaluated by PCAC beginning July 2026. Not yet Category 1 — awaiting formal PCAC review.
Dosing based on small human studies or early-phase trials. Not established by Phase 3 evidence.
Regulatory Status
Status based on publicly available FDA communications. Verify at FDA.gov for authoritative guidance.
View full regulatory timeline →Titration Protocols
Research Protocol
Source: Dolotov et al., Brain Research, 2006
| Dose | Duration | Draw (3 mg vial in 2mL) | Notes |
|---|---|---|---|
| 300 mcg | Maintenance | 0.20 mL (20 units) | Standard research dose |
Available Vial Sizes
3 mg
3 mg vial
5 mg
5 mg vial
Citations
- [1]Semax, an Analog of ACTH(4-10) with Cognitive Effects, Regulates BDNF and trkB Expression in the Rat Hippocampus. Brain Research, 1170, 35-42. Link(Reviewed: 2026-04-16)